Iovance Biotherapeutics First Quarter 2025 Earnings: Misses Expectations
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $20
Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $25
Mizuho Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Announces Target Price $10
Iovance Biotherapeutics' Earnings Call: Mixed Sentiments and Future Prospects
U.S. Small Caps End Mixed As Regencell Bioscience Lead, Iovance Biotherapeutics Lags
Top Midday Decliners
12 Health Care Stocks Moving In Friday's Intraday Session
Iovance Biotherapeutics Stock Sinks Nearly 50% Intraday. Here's Why the Biotech Is Tumbling
Iovance Biotherapeutics Down Over 47%, On Track for Lowest Close Since June 2013 -- Data Talk
Iovance Biotherapeutics Cut to Market Perform From Market Outperform by JMP Securities
Expert Outlook: Iovance Biotherapeutics Through The Eyes Of 9 Analysts
Sector Update: Health Care Stocks Flat to Higher Premarket Friday
Sector Update: Health Care
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), GH Research (GHRS) and NewAmsterdam Pharma Company (NAMS)
US Equity Futures Higher as Trump Considers 80% China Tariffs
Expedia, Wolfspeed, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Baird Downgrades Iovance Biotherapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $20
Dave To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday
Iovance Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.